Mothers, we need your help!
The drug that we will use to prevent FNAIT can only be made from plasma from women who have previously given birth to an FNAIT child.
Please sign up as plasma donor, if you have given birth to an FNAIT child and want to help us save the lives of babies at risk of developing FNAIT
Some excessive bleedings in foetuses and neonates occur because there are too few blood platelets to stop the bleeding. This may be caused by Foetal Neonatal Alloimmune Thrombocytopenia (FNAIT).
is an EU-funded collaborative project aiming to develop a safe new treatment that prevents excessive bleeding in foetuses and newborns caused by FNAIT.
Plasma from women who have had a foetus/child with FNAIT is needed to produce the new drug that can prevent FNAIT. We strongly encourage these women to donate plasma for production of this drug.
The PROFNAIT consortium was represented by a booth in the exhibitor area and a poster at the scientific part of the SMFM 34th Annual Meeting-The Pregnancy Meeting in New Orleans in the USA, February 3-8.
We would like to thank Professor James Bussel at Weill Medical College of Cornell University for a great oral presentation at the conference, highlighting the PROFNAIT consortium (3 photos) … See MoreSee Less
7 months ago ·
Time to introduce screening?
An article in the Norwegian scientific journal Bioingeniøren (www.nito.no/dm/public/380037.PDF) is focused on whether or not it is time to introduce HPA-1bb screening of pregnant women.
The authors of a screening and intervention study from, which included more than 100.000 women, strongly suggest that early diagnosis contribute to reduce the morbidity and mortality due to FNAIT. After nearly 10 years, the Norwegian health authorities still have not introduced screening, but stress that a prophylactic treatment with satisfactory effect might change their decision.
The article is unfortunately only available in norwegian. … See MoreSee Less
7 months ago ·